EUVIMEDDécouvrir EUVIMED
Open access

Magnetically actuated nanoantennas for wireless glioblastoma therapy

Monochura Saha iD, Ishaq N Khan, Baju Joy iD, Shun-Ying Chen iD, Hao-Tung Yang, Preet Patel iD, Kyuho Jang iD, Pengrui Zhang iD, Faheem Azeemi, Deblina Sarkar iD

Science Advances · 2026

DOI: 10.1126/sciadv.aeb1237 ↗

At a glance

Journal article in Science Advances, 2026. Written by Monochura Saha and 9 co-authors. Institution: MIT Media Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Major MEDLINE topics: Glioblastoma, Brain Neoplasms, Wireless Technology. 108 references. The full text is freely available in PubMed Central. Funded by: The ChadTough Defeat DIPG Foundation, The Sontag Foundation Distinguished Scientist Award.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Glioblastoma (GBM) remains a formidable clinical challenge, characterized by invasive growth, therapeutic resistance, and dismal patient survival. We report the development of HITMAN (highly localized electric field–induced tumor therapy using magnetically actuated nanoantennas), a wireless bioelectric therapy that selectively eradicates GBM cells with cellular precision. Magnetically actuated nanoantennas convert low-frequency (≤200 kHz), deep-brain–penetrant magnetic fields into localized electric fields, thereby triggering protein unfolding, membrane disruption, and ER stress. In vitro, HITMAN demonstrated superior efficacy compared to temozolomide (TMZ), significantly decreasing viability in drug-resistant, patient-derived GBM cells by 52.2%, versus 10% with TMZ while sparing neurons and astrocytes. Mechanistically, HITMAN activated the unfolded protein response and autophagy pathways, suppressed cell cycle and adhesion genes, reduced Ki-67 expression, disrupted cytoskeletal architecture, and elevated p53 levels, underscoring a multifaceted antitumor mechanism. In orthotopic mouse models, HITMAN significantly inhibited tumor growth, extended median survival by more than 50%, and exhibited no systemic toxicity. Thus, HITMAN offers a minimally invasive, spatially precise, and clinically translatable therapy for GBM.

Subjects

MeSH terms (MEDLINE)

GlioblastomaBrain NeoplasmsWireless TechnologyHumansAnimalsMiceCell Line, TumorTemozolomideXenograft Model Antitumor Assays

Substances

Temozolomide

Authors and institutions

  • MIT Media Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

ORCID profiles: Monochura Saha, Baju Joy, Shun-Ying Chen, Preet Patel, Kyuho Jang, Pengrui Zhang, Deblina Sarkar

Funding

  • The ChadTough Defeat DIPG Foundation
  • The Sontag Foundation Distinguished Scientist Award

Cite

APA

Saha, M., Khan, I. N., Joy, B., Chen, S. Y., Yang, H. T., Patel, P., Jang, K., Zhang, P., Azeemi, F., & Sarkar, D. (2026). Magnetically actuated nanoantennas for wireless glioblastoma therapy. Science Advances. https://doi.org/10.1126/sciadv.aeb1237

Vancouver

Saha M, Khan IN, Joy B, Chen SY, Yang HT, Patel P, et al. Magnetically actuated nanoantennas for wireless glioblastoma therapy. Science Advances. 2026. doi:10.1126/sciadv.aeb1237

BibTeX
@article{Saha2026,
  author = {Saha, Monochura and Khan, Ishaq N and Joy, Baju and Chen, Shun-Ying and Yang, Hao-Tung and Patel, Preet and Jang, Kyuho and Zhang, Pengrui and Azeemi, Faheem and Sarkar, Deblina},
  title = {Magnetically actuated nanoantennas for wireless glioblastoma therapy},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aeb1237}
}
Start for free →